Compare Abeona Therapeutics Inc (ABEO) vs DigitalOcean Holdings Inc (DOCN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs DigitalOcean Holdings Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while DigitalOcean Holdings Inc trades at $139.24 (market cap $14.30B). The key difference: DigitalOcean Holdings Inc is far larger — about 38.3× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, DigitalOcean Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | DOCN | |
|---|---|---|
Market Cap | $373.32M | $14.30B |
Sector | Health | Technology |
52-Week High | $7.23 | $181.29 |
52-Week Low | $4.17 | $25.74 |
Enterprise Value | $228.22M | $14.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
DigitalOcean (DOCN) trades at $137.12, up 5.37% today amid strong Q2 2026 preliminary results showing accelerated growth. The stock exhibits bearish technical signals but maintains robust fundamentals with consistent earnings beats, 58.49% gross margins, and 24.97% net income margins. Recent news highlights inclusion in the Russell 1000 Index and AI-driven cloud demand, with analyst consensus bullish at a $169.91 price target.
Outlook remains positive given AI-native cloud positioning and revenue growth, though high valuation ratios (P/E 57.62) and negative shareholder equity pose risks. Upside depends on execution of growth initiatives, while competition and debt levels warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →
